Market Currents
Medivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA...
-
Friday, August 31, 2012, 4:03 PM ETMedivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA announcement of an early approval for it and Astellas Pharma's enzalutamide capsules for the treatment of patients with metastatic castration-resistant prostate cancer.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
